Ovarian Cancer
If it’s your first time on this website, please read the disclaimer section.
Jul 13 – Jul 20, 2026
Systemic Treatment of Ovarian Cancer Recurrence: ASCO Living Guideline, Version 2026.1.0.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This ASCO Living Guideline provides evidence-based recommendations for systemic treatment of recurrent high-grade serous or endometrioid ovarian, fallopian tube, or primary peritoneal cancer. Based on a systematic review of 147 RCTs and systematic reviews, key findings include strong recommendations for platinum-based combination regimens (PLD plus carboplatin, paclitaxel plus carboplatin, gemcitabine plus carboplatin) in platinum-sensitive disease, with bevacizumab as an optional addition. For platinum-resistant disease with FRα expression, mirvetuximab soravtansine is strongly recommended, alongside options like PLD monotherapy, weekly paclitaxel, or relacorilant plus nab-paclitaxel. These recommendations directly support clinicians in selecting systemic therapies for recurrent ovarian cancer, a primary cancer focus, with clear numerical evidence from the included trials.
10.1200/JCO-26-01591
Jun 22 – Jun 29, 2026
Long-Term Outcomes in Patients With Recurrent Ovarian Cancer and Exceptional Response to PARP Inhibitors.
JAMA ONCOL · Q1 JOURNAL - RANK #14/326TOP-TIER
This international, multicenter, retrospective cohort study investigated long-term outcomes and genotype-phenotype associations in 320 platinum-sensitive recurrent ovarian cancer patients with exceptional PARP inhibitor response (PFS ≥ 5 years). With a median follow-up of 6.8 years, 7.5-year and 10-year PFS rates were 88.8% and 78.7%, respectively, demonstrating sustained progression-free survival. Notably, patients discontinuing PARP inhibitors without progression achieved a 10-year PFS of 90.1% versus 72.5% for those continuing, with a low 1.6% risk of late-onset MDS/AML. These results provide crucial guidance for counseling on PARP inhibitor duration, suggesting functional cure is possible and informing decisions on treatment cessation in ovarian cancer.
10.1001/jamaoncol.2026.1924
Jun 15 – Jun 22, 2026
Antibody-drug conjugates in gynaecological cancers: opportunities and challenges.
NAT REV CLIN ONCOL · Q1 JOURNAL - RANK #2/326TOP-TIER
This review provides an overview of antibody-drug conjugates (ADCs) in gynaecological malignancies, detailing key advances and future opportunities. It highlights three ADCs currently approved for previously treated gynaecological cancers: mirvetuximab soravtansine for folate receptor-α-positive ovarian cancer, trastuzumab deruxtecan for HER2-expressing (3+ IHC) solid tumours, and tisotumab vedotin for cervical cancer. The abstract discusses current research priorities including novel targets, resistance mechanisms, sequencing strategies, toxicity management, and rational combinations, such as ADCs with immune checkpoint inhibitors. This offers clinicians a comprehensive update on ADC applications in gynaecological cancers, directly aligning with an interest in cancer-focused research and informing practical treatment considerations.
10.1038/s41571-026-01164-9
Jun 01 – Jun 08, 2026
International disruptions to cancer diagnosis and stage at presentation during the COVID-19 pandemic in 2020: an International Cancer Benchmarking Partnership (ICBP) population-based study.
LANCET ONCOL · Q1 JOURNAL - RANK #8/326TOP-TIER
This population-based study analyzed 2.6 million patients across seven countries to evaluate how the COVID-19 pandemic disrupted the incidence and staging of seven major cancer types in 2020. Researchers found that 16% (55,713) of expected cancer cases were missing between April and December 2020, with the highest deficits occurring in prostate (24%), breast (18%), and melanoma (18%) diagnoses. The data reveals significant regional variations, such as a 54% deficit in UK prostate cancer cases, highlighting critical gaps in screening and diagnostic access during lockdowns. These findings underscore a pressing clinical need to address diagnostic backlogs and monitor for potential stage shifts in patients whose diagnoses were delayed by pandemic-related healthcare barriers.
10.1016/S1470-2045(26)00089-6
May 04 – May 11, 2026
Malignant Adult Ovarian Germ Cell Tumors: An International Multicenter Study to Identify Relevant Prognostic Risk Factors for Stage IC and Beyond.
J CLIN ONCOL · Q1 JOURNAL - RANK #6/326TOP-TIER
This international multicenter study analyzed 254 patients with stage IC-IV malignant ovarian germ cell tumors (MOGCTs) to identify prognostic risk factors influencing survival. Multivariable analysis revealed that age ≥35 years (HR 2.8), stage III/IV disease (HR 1.4), and nondysgerminoma histology (HR 7.3) significantly worsened cancer-specific survival (CSS). The study demonstrated a 10-year CSS of 83.2% and highlighted that high-dose chemotherapy improves survival outcomes specifically during the first relapse rather than subsequent ones. These findings provide clinicians with critical evidence for risk-stratifying patients and optimizing treatment intensity for advanced-stage MOGCTs, particularly regarding the timing of aggressive salvage therapies.
10.1200/JCO-25-00840